Home | Meeting coverage | ACR 2021

 This information is brought to you by high5immunology.TV and is not sponsored by, nor a part of, the American College of Rheumatology. 

Spotlight Discussions

ACR 2021

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

New treatment alternative in GCA: promising secukinumab...

TitAIN

ACR 2021

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

Dear Doctor: JAKi risk factors and safety profile - is...

ORAL Surveillance

ACR 2021

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

ARIAA: prevention study or very early treatment of RA?

ARIAA

ACR 2021

A. Askari, F. Behrens, P. Sewerin, V. Goeb, E. Lubrano, X. Michelena Vegas

IL-17 pathway important for pain in PsA

SPIRIT-H2H

ACR 2021

E. Choy, P. Sewerin, F. Behrens, T. Kvien, A. Balsa, A. Rubbert-Roth

Pulmonary involvement and possible therapy concepts in...

TRAIL1

ACR 2021

A. Askari, F. Behrens, P. Sewerin, V. Goeb, E. Lubrano, X. Michelena Vegas

axPsA is axSpA is not...!?

DISCOVER 1&2, PSUMMIT

ACR 2021

A. Askari, F. Behrens, P. Sewerin, V. Goeb, E. Lubrano, X. Michelena Vegas

No need for methotrexate in ustekinumab treatment in...

MUST

Rheumatoid arthritis – ENG

ACR 2021

Ernest Choy, MD

Should we use ultra-low-dose rituximab during the...

N3C, REDO

ACR 2021

Alejandro Balsa, MD, PhD

Statins reduce cardiovascular risk and​ mortality -...

ACR 2021

Vincent Goeb, MD, PhD

Nausea & alopecia with MTX in RA

RAMS

ACR 2021

Alejandro Balsa, MD, PhD

Tofacitinib is associated with a slightly increased...

ORAL Surveillance

ACR 2021

Vincent Goeb, MD, PhD

We need predictors of response for RA treatment

ACR 2021

Andrea Rubbert-Roth, MD

Long awaited - MACE data from ORAL surveillance

ORAL Surveillance

ACR 2021

Vincent Goeb, MD, PhD

Discordance between patients and physicians in RA

ACR 2021

Tore Kvien, MD

Cycling JAKi compared to switching to biologic DMARD in...

JAK-pot

ACR 2021

Ernest Choy, MD

Cardiovascular disease in RA

ORAL Surveillance, National VA registry (U.S.)

ACR 2021

Alejandro Balsa, MD, PhD

Abatacept may reduce subclinical inflammation in RA-at...

ARIAA

Rheumatoid arthritis – FRA/GER/ESP/NOR

ACR 2021

Tore Kvien, MD

Skifte mellom JAK hemmere sammenliknet med skifte til...

JAK-pot

ACR 2021

Alejandro Balsa, MD, PhD

Tofacitinid se asocia con un ligero incremento del...

ORAL Surveillance

ACR 2021

Vincent Goeb, MD, PhD

Quels marqueurs de réponse aux traitements dans la...

ACR 2021

Andrea Rubbert-Roth, MD

Lange erwartet - MACE-Daten zur ORAL Surveillance

ORAL Surveillance

ACR 2021

Vincent Goeb, MD, PhD

Désaccords patient/Médecin : se comprendre pour plus...

ACR 2021

Alejandro Balsa, MD, PhD

Abatacept reduce la inflamación subclínica en pacientes...

ARIAA

ACR 2021

Vincent Goeb, MD, PhD

Quels effets indésirables peuvent être associés à la...

RAMS

ACR 2021

Alejandro Balsa, MD, PhD

Las estatinas reducen el riesgo cardiovascular y la...

Psoriatic arthritis – ENG

ACR 2021

Ennio Lubrano, MD, PhD

Comparison of composit indices for disease activity in...

SELECT-PsA 1

ACR 2021

Philipp Sewerin, MD

Osteoporosis in PsA

ACR 2021

Xabier Michelena Vegas, MD

Axial PsA MRI data

MAXIMISE

ACR 2021

Frank Behrens, MD

No need for MTX in ustekinumab-treated patients

MUST

ACR 2021

Philipp Sewerin, MD

Upadacitinib in PsA

Select PsA 1 und 2

ACR 20221

Frank Behrens, MD

Anemia is an issue in PsA - proper treatment possible!

DISCOVER 1&2

ACR 2021

Francesco Ciccia, MD, PhD

Association of C-reactive protein and non-steroidal...

ACR 2021

Philipp Sewerin, MD

Joint effusions and enthesitis after physical exertion

ACR 2021

Philipp Sewerin, MD

PET/CT in diagnosis for PsA

ACR 2021

Frank Behrens, MD

Pain differs: Superior effect of IL-17-inhibition vs....

SPIRIT-H2H

ACR 2021

Philipp Sewerin, MD

Tildrakizumab in PsA

ACR 2021

Philipp Sewerin, MD

Secukinumab vs TNF-α blockers in enthesitis

ACR 2021

Frank Behrens, MD

Guselkumab: the better ustekinumab?!

DISCOVER 1&2, PSUMMIT

ACR 2021

Philipp Sewerin, MD

Guselkumab in axial symptoms

DISCOVER 1&2

ACR 2021

Francesco Ciccia, MD, PhD

Prediction of psoriatic arthritis in patients with...

Psoriatic arthritis – GER/ESP/ITA

ACR 2021

Ennio Lubrano, MD, PhD

Studio di confronto tra i vari indici compositi per la...

SELECT-PsA 1

ACR 2021

Frank Behrens, MD

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

MUST

ACR 2021

Philipp Sewerin, MD

Upadacitinib bei PsA

Select PsA 1 und 2

ACR 2021

Xabier Michelena Vegas, MD

Datos de RM en APs axial

MAXIMISE

ACR 2021

Philipp Sewerin, MD

Secukinumab vs TNF-α Blocker bei Enthesitis

ACR 2021

Francesco Ciccia, MD, PhD

Associazione di livelli di PCR e uso di FANS con gli...

ACR 2021

Frank Behrens, MD

Anämie bei PsA ist ein Thema - effektive Therapie...

DISCOVER 1&2

ACR 2021

Philipp Sewerin, MD

Tildrakizumab bei PsA

ACR 2021

Frank Behrens, MD

Schmerz ist nicht gleich Schmerz: Unterschied von...

SPIRIT-H2H

ACR 2021

Philipp Sewerin, MD

PET-CT zur Quantifizierung der Entzündung

ACR 2021

Frank Behrens, MD

Guselkumab: das bessere Ustekinumab?!

DISCOVER 1&2, PSUMMIT

ACR 2021

Philipp Sewerin, MD

Gelenkergüsse und Enthesitis nach körperlicher...

ACR 2021

Philipp Sewerin, MD

Osteoporose bei PsA

ACR 2021

Francesco Ciccia, MD, PhD

Previsione di sviluppo di artrite psoriasica in...

ACR 2021

Philipp Sewerin, MD

Guselkumab bei axialer Symptomatik

DISCOVER 1&2

Axial Spondyloarthritis – ENG

ACR 2021

Xabier Michelena Vegas, MD

JAK inhibitors - new kids on the block

SELECT-AXIS 1

ACR 2021

Xabier Michelena Vegas, MD

Axial PsA MRI data

MAXIMISE

ACR 2021

Francesco Ciccia, MD, PhD

Self-monitoring of disease activity with a smartphone...

ACR 2021

Xabier Michelena Vegas, MD

Dose tapering of TNF inhibitors in axSpA

Axial Spondyloarthritis – ESP/ITA

ACR 2021

Xabier Michelena Vegas, MD

Optimización de iTNF en EspAax

ACR 2021

Xabier Michelena Vegas, MD

Inhibidores JAK: nuevas dianas en EspAax

SELECT-AXIS 1

ACR 2021

Xabier Michelena Vegas, MD

Datos de RM en APs axial

MAXIMISE

ACR 2021

Francesco Ciccia, MD, PhD

l’auto-monitoraggio di malattia è fattibile nella...

Lupus erythematosus – ENG

ACR 2021

Bimba Franziska Hoyer, MD

JAKi baricitinib successfully mastered phase II study

ACR 2021

Bimba Franziska Hoyer, MD

Not yet a new standard: belimumab + rituximab

BLISS-BELIEVE

Lupus erythematosus – GER

ACR 2021

Bimba Franziska Hoyer, MD

Kombination Belimumab und Rituximab noch kein neuer...

BLISS-BELIEVE

ACR 2021

Bimba Franziska Hoyer, MD

JAK-Inhibitor Baricitinib in Phase II erfolgreich

Vasculitis – ENG

ACR 2021

Carlo Salvarani, MD

Baricitinib in relapsing giant cell arteritis

ACR 2021

Carlo Salvarani, MD

Secukinumab in giant cell arteritis

TitAIN

ACR 2021

Andrea Rubbert-Roth, MD

A new therapeutic approach for giant cell arteritis?

TitAIN

ACR 2021

Carlo Salvarani, MD

PET as a predictor of vascular damage in large-vessel...

Vasculitis – GER/ITA

ACR 2021

Carlo Salvarani, MD

Baricitinib nell'arterite a cellule giganti recidivante

ACR 2021

Carlo Salvarani, MD

Secukinumab nell'arterite a cellule giganti

TitAIN

ACR 2021

Andrea Rubbert-Roth, MD

Neuer Therapieansatz für die Riesenzellarteriitis?

TitAIN

ACR 2021

Carlo Salvarani, MD

Il ruolo della PET nel predire il danno vascolare nelle...

COVID-19 – ENG

ACR 2021

Bimba Franziska Hoyer, MD

Breakthrough infections after SARS-CoV2-vaccination -...

N3C Registry

ACR 2021

Tore Kvien, MD

Immune responses to COVID-19 vaccines

ACR 2021

Ayman Askari, MD

Anticytokine antibodies causing severe microbacterial...

ACR 2021

Bimba Franziska Hoyer, MD

TNF blockers reduce the antibody response to RNA...

SCQM Registry

ACR 2021

Ernest Choy, MD

Should we use ultra-low-dose rituximab during the...

N3C, REDO

ACR 2021

Bimba Franziska Hoyer, MD

Breakthrough infections after SARS-CoV2-vaccination -...

COVID-19 Global Rheumatology Alliance registry

ACR 2021

Ayman Askari, MD

Impact of COVID-19 on patients with rheumatic diseases

ACR 2021

Bimba Franziska Hoyer, MD

Vaccination against Delta variant worse in patients...

ACR 2021

Bimba Franziska Hoyer, MD

Booster with which one if there is no seroconversion?

ACR 2021

Ayman Askari, MD

Analysis of COVID-19 infection among vaccinated...

COVID-19 – GER/NOR

ACR 2021

Bimba Franziska Hoyer, MD

Womit boostern bei fehlender Serokonversion?

ACR 2021

Bimba Franziska Hoyer, MD

Durchbruchsinfektionen nach SARS-CoV2-Impfung -...

N3C Register

ACR 2021

Bimba Franziska Hoyer, MD

Durchbruchsinfektionen nach SARS-CoV2-Impfung -...

COVID-19 Global Rheumatology Alliance registry

ACR 2021

Bimba Franziska Hoyer, MD

TNF-Blocker reduzieren Antikörperantwort bei...

SCQM Register

ACR 2021

Tore Kvien, MD

Immunresponser til COVID-19 vaksiner

ACR 2021

Bimba Franziska Hoyer, MD

Schlechtere Neutralisation der Delta-Variante unter...

Varia – ENG

ACR 2021

Ayman Askari, MD

Skin findings in patients of color with rheumatic...

ACR 2021

Andrea Rubbert-Roth, MD

New exciting data - dietary supplements with vitamin D...

VITAL

ACR 2021

Ayman Askari, MD

PROs from a real-world study on etanercept biosimilar -...

COMPACT

ACR 2021

Ayman Askari, MD

CBD - an alternative therapy for chronic pain

ACR 2021

Tore Kvien, MD

Therapeutic drug monitoring - a randomized controlled...

NOR-DRUM B

ACR 2021

Ayman Askari, MD

Pearls and myths in rheumatology

Varia – GER/NOR

ACR 2021

Tore Kvien, MD

Monitorering av legemiddelkonsentrasjoner (Therapeutic...

NOR-DRUM B

ACR 2021

Andrea Rubbert-Roth, MD

Neue spannende Daten - Nahrungsergänzung mit Vitamin D...

VITAL